ROMAZICON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROMAZICON (ROMAZICON).
Competitive antagonist at the GABA-A receptor benzodiazepine binding site, reversing benzodiazepine effects.
| Metabolism | Hepatic metabolism via hydrolysis to inactive metabolites; major metabolite is a carboxylic acid derivative. |
| Excretion | Renal: >90% as metabolites, <1% unchanged; biliary/fecal: minor |
| Half-life | Terminal half-life 40-80 min; clinically repeated doses may be needed due to shorter duration than benzodiazepines |
| Protein binding | ~66% bound to serum albumin |
| Volume of Distribution | 0.8-1.0 L/kg; indicates moderate tissue distribution |
| Bioavailability | IV: 100% |
| Onset of Action | IV: 1-2 minutes; peak effect within 6-10 minutes |
| Duration of Action | Approximately 1-2 hours (reversal of sedation); may be shorter than long-acting benzodiazepines, requiring repeat dosing |
| Molecular Weight | 303.33 |
0.2 mg IV over 15 seconds, repeated at 1-minute intervals up to 1 mg; may repeat after 20 minutes if needed.
| Dosage form | INJECTABLE |
| Renal impairment | No adjustment required for renal impairment. |
| Liver impairment | Reduced clearance in hepatic impairment; consider dose reduction and slow administration; no specific Child-Pugh guidelines. |
| Pediatric use | Neonates and infants: 0.01 mg/kg IV (max 0.2 mg) at 1-minute intervals up to 1 mg. Children: 0.02 mg/kg IV (max 0.2 mg) at 1-minute intervals up to 1 mg. |
| Geriatric use | Initiate with 0.1 mg IV; titrate cautiously due to increased sensitivity and prolonged elimination. |
| 1st trimester | Avoid use unless clearly indicated; limited data in human pregnancy. Flumazenil crosses the placenta; animal studies show no teratogenicity, but risk cannot be excluded. |
| 2nd trimester | Avoid use unless clearly indicated; potential for withdrawal symptoms in neonate if used shortly before delivery. |
| 3rd trimester | Avoid use unless clearly indicated; may precipitate withdrawal in benzodiazepine-dependent mothers and neonates; use only for reversal of benzodiazepine sedation. |
Clinical note
Comprehensive clinical and safety monograph for ROMAZICON (ROMAZICON).
| Placental transfer | Flumazenil crosses the placenta; serum concentrations in cord blood are approximately 50% of maternal levels. |
| Breastfeeding | Flumazenil is excreted into breast milk in low concentrations. However, due to risk of withdrawal or sedation in the infant, caution is advised. Consider delaying breastfeeding until drug has been eliminated (half-life ~1 hour). |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to flumazenil or any componentPatients receiving benzodiazepines for control of life-threatening conditions (e.g., status epilepticus, increased intracranial pressure)Tricyclic antidepressant overdose with signs of QRS widening or arrhythmia
| Precautions | Seizures, particularly in patients with epilepsy or mixed overdose (e.g., tricyclic antidepressants), Hypoventilation may recur due to short duration of flumazenil vs. long-acting benzodiazepines, Panic reactions in benzodiazepine-dependent patients |
| Food/Dietary | No clinically significant food interactions reported. Avoid grapefruit juice as it may theoretically affect CYP3A4 metabolism, though clinical relevance is minimal due to intravenous administration. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal studies have not shown evidence of teratogenicity. Risk cannot be excluded; use only if clearly needed. First trimester: unknown risk. Second and third trimesters: no specific fetal risks identified, but benzodiazepine receptor antagonists may induce withdrawal in neonates exposed to benzodiazepines. |
| Fetal Monitoring | Monitor maternal vital signs and level of consciousness. Fetal heart rate monitoring if used near term due to potential for neonatal withdrawal. |
| Fertility Effects | No data on fertility effects in humans. Animal studies have not shown impaired fertility. |
| Clinical Pearls | Reversal of benzodiazepine effects with flumazenil may precipitate acute withdrawal or seizures, especially in patients on chronic benzodiazepine therapy or with tricyclic antidepressant overdose. Administer in small titrated doses (0.2 mg IV over 30 seconds) and repeat at 1-minute intervals as needed, up to a maximum of 1 mg. Duration of action is shorter than most benzodiazepines; monitor for resedation and consider repeat doses. Not recommended for treatment of benzodiazepine withdrawal or long-term sedation reversal outside of procedural settings. |
| Patient Advice | This medication is used to reverse the effects of benzodiazepines, such as sedation or breathing problems. · You may feel more awake quickly after receiving this medicine, but effects may wear off within 1-2 hours and sedation could return. · Tell your doctor immediately if you experience seizures, irregular heartbeat, or severe anxiety after receiving this medication. · Do not drive or operate heavy machinery for at least 24 hours after flumazenil administration, as sedation may recur. · If you take benzodiazepines regularly, you may experience withdrawal symptoms such as anxiety, agitation, or muscle twitching. · This medication does not reverse the effects of opioids, alcohol, or other sedatives. |